Literature DB >> 29624895

How I investigate Clonal cytogenetic abnormalities of undetermined significance.

G Tang1, L J Medeiros1, S A Wang1.   

Abstract

Myelodysplastic syndromes are a group of hematopoietic stem cell diseases characterized by cytopenia(s), morphological dysplasia, and clonal hematopoiesis. In some patients, the cause of cytopenia(s) is uncertain, even after thorough clinical and laboratory evaluation. Evidence of clonal hematopoiesis has been used to support a diagnosis of myelodysplastic syndrome in this setting. In patients with cytopenia(s), the presence of clonal cytogenetic abnormalities, except for +8, del(20q) and -Y, can serve as presumptive evidence of myelodysplastic syndrome. Recent advances in next-generation sequencing have detected myeloid neoplasm-related mutations in patients who do not meet the diagnostic criteria for myelodysplastic syndrome. Various terms have been adopted to describe these cases, including clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). Similarly, studies have shown that certain chromosomal abnormalities, including ones commonly detected in myelodysplastic syndrome, may not be associated necessarily with an underlying myelodysplastic syndrome. These clonal cytogenetic abnormalities of undetermined significance (CCAUS) are similar to CHIP and CCUS. Here, we review the features of CCAUS, distinguishing CCAUS from clonal cytogenetic abnormalities associated with myelodysplastic syndrome, and the potential impact of CCAUS on patient management.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  clonal cytogenetic abnormalities; myelodysplastic syndromes; unknown significance

Mesh:

Year:  2018        PMID: 29624895     DOI: 10.1111/ijlh.12826

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  5 in total

1.  Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.

Authors:  Machiko Fujioka; Hidehiro Itonaga; Takeharu Kato; Yasuhito Nannya; Miki Hashimoto; Sachie Kasai; Eo Toriyama; Rena Kamijo; Masataka Taguchi; Hiroaki Taniguchi; Shinya Sato; Sunao Atogami; Yoshitaka Imaizumi; Tomoko Hata; Yukiyoshi Moriuchi; Seishi Ogawa; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2019-09-12       Impact factor: 2.490

2.  Clonal dominance of a donor-derived del(20q) clone after allogeneic hematopoietic stem cell transplantation in an acute myeloid leukemia patient with del(20q).

Authors:  Jung Yoon; Jae Won Yun; Chul Won Jung; Hee-Jin Kim; Sun-Hee Kim
Journal:  J Clin Lab Anal       Date:  2019-06-11       Impact factor: 2.352

3.  Pattern of chromosomal aberrations persisting over 30 years in a Chernobyl Nuclear Power Plant accident survivor: study using mFISH.

Authors:  Victoriya Nikitina; Vladimir Nugis; Tatiyana Astrelina; Diana Zheglo; Irina Kobzeva; Mariya Kozlova; Irina Galstyan; Elena Lomonosova; Aliy Zhanataev; Tatiyana Karaseva; Alexander S Samoylov
Journal:  J Radiat Res       Date:  2022-03-17       Impact factor: 2.724

4.  Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality.

Authors:  Shinya Rai; J Luis Espinoza; Yasuyoshi Morita; Hirokazu Tanaka; Itaru Matsumura
Journal:  Front Immunol       Date:  2019-01-09       Impact factor: 7.561

5.  [Progress in pre-myelodysplastic syndrome conditions].

Authors:  W Zhang; R Fu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.